Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomised controlled NOH-PE trial.
about
Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophiliaProphylaxis for venous thromboembolic disease in pregnancy and the early postnatal periodDrugs for treatment of very high blood pressure during pregnancyAntithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunctionAntithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunctionDrugs for treatment of very high blood pressure during pregnancyThrombophilia and Pregnancy ComplicationsPrevention of pre-eclampsia by low-molecular-weight heparin in addition to aspirin: a meta-analysisLow-molecular-weight heparin for prevention of placenta-mediated pregnancy complications: protocol for a systematic review and individual patient data meta-analysis (AFFIRM).Early detection of maternal risk for preeclampsiaIndividual risk assessment of adverse pregnancy outcome by multivariate regression analysis may serve as basis for drug intervention studies: retrospective analysis of 426 high-risk patients including ethical aspectsHeparin rescues factor V Leiden-associated placental failure independent of anticoagulation in a murine high-risk pregnancy model.Management of inherited thrombophilia in pregnancy.Thrombosis in women: what are the knowledge gaps in 2013?Antithrombotic treatment for pregnancy complications: which path for the journey to precision medicine?Overview of low molecular weight heparin for preventative treatment of adverse obstetric outcomes related to abnormal placentation.LMWH to prevent placenta-mediated pregnancy complications: an update.Maternal and feto-placental phenotypes of early-onset severe preeclampsia.'To test or not to test', the arguments for and against thrombophilia testing in obstetrics.Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial Doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results.Is thrombophilia associated with placenta-mediated pregnancy complications? A prospective cohort study.The Fetal Safety of Enoxaparin Use During Pregnancy: A Population-Based Retrospective Cohort Study.Low-molecular-weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT: a rebuttal.Low molecular weight heparin modulates maternal immune response in pregnant women and mice with thrombophilia.Low molecular weight heparin: does it represent a clinical opportunity for preventing preeclampisa associated with fetal growth restriction?Preeclampsia in pregnancies complicated by systemic lupus erythematosus (SLE) nephritis: prophylactic treatment with multidisciplinary approach are important keys to prevent adverse obstetric outcomes.Heparin promotes soluble vascular enothelial growth factor receptor expression in human placental villi: a rebuttal.
P2860
Q24194917-9AF5CBEA-2280-4657-B170-1ACBD8DBF1CFQ24200433-9F5EE62F-F3D6-454F-A449-9020CDBC4A55Q24200974-C540261E-5895-4E65-9DE9-10CC135FF0CAQ24201073-A50F6775-F5CD-4CAE-8C0D-37A45C714E81Q24235012-CAFCE6DE-EA54-49C3-B141-E6D3C3219F52Q24244908-6512BE50-F991-4C2E-8553-E23B140107D8Q26775078-EC7444E5-D8B8-42E5-8595-DB8C2CED1DFDQ26781800-2C6C3960-913D-48A1-884F-3A9C0379593FQ30833556-76D4D2A7-9736-4F29-B358-613AB3280E17Q36125098-2ECE57EF-56AB-4932-A698-511B803EB6A6Q36927599-0D9C5FB6-082F-4AB5-8B59-5FAC639B9030Q37634740-AD15F5CF-1B4D-4047-90AD-E91E06CF8E5AQ37730086-EAE977DC-3620-415E-A822-03A4F2CC82B1Q38117735-89EAC4B7-457B-45CF-8336-091BAA9A5423Q38193203-8D57E0CA-24A0-4A0E-ACE6-F96949D9B0D4Q38206136-95D8D25A-D83E-4F0F-96BF-91D6184E81C8Q38268419-AC73FD47-4BCC-46A9-B645-FEA626CED9AFQ38486673-3D443458-7291-4CB5-AEA2-A1544BF245DCQ38692085-9F7E07A5-6324-4A39-A4D9-7B580D476D4CQ41699981-10FC11CE-C456-4CAC-B021-6769B1134699Q44113152-61ED01F8-4159-4F4F-A00C-0ACE946250F8Q46303410-05080B41-094B-47BD-8C92-B7C83C1B520EQ47319179-2A99510D-8795-4DF0-993D-62158E00E9B8Q47419189-8CECC64D-B58C-45B9-A0CF-37F72A648E95Q47436041-18B58F1E-646A-4C89-9E99-7BBCEDB99CDDQ47609396-5AC77D82-08A0-4199-A51E-CEEB781C99ACQ54536401-E50046C4-CFF5-459E-B7DF-7347518759A0
P2860
Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomised controlled NOH-PE trial.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Addition of enoxaparin to aspi ...... mised controlled NOH-PE trial.
@ast
Addition of enoxaparin to aspi ...... mised controlled NOH-PE trial.
@en
type
label
Addition of enoxaparin to aspi ...... mised controlled NOH-PE trial.
@ast
Addition of enoxaparin to aspi ...... mised controlled NOH-PE trial.
@en
prefLabel
Addition of enoxaparin to aspi ...... mised controlled NOH-PE trial.
@ast
Addition of enoxaparin to aspi ...... mised controlled NOH-PE trial.
@en
P2093
P356
P1476
Addition of enoxaparin to aspi ...... mised controlled NOH-PE trial.
@en
P2093
Bassam Haddad
Céline Chauleur
Isabelle Quéré
Jean-Yves Lefrant
Michel Dauzat
Nicolas Molinari
Pierre Marès
P304
P356
10.1160/TH11-05-0340
P577
2011-09-22T00:00:00Z